ATE339200T1 - Behandlung von hyperurikämie - Google Patents

Behandlung von hyperurikämie

Info

Publication number
ATE339200T1
ATE339200T1 AT03292973T AT03292973T ATE339200T1 AT E339200 T1 ATE339200 T1 AT E339200T1 AT 03292973 T AT03292973 T AT 03292973T AT 03292973 T AT03292973 T AT 03292973T AT E339200 T1 ATE339200 T1 AT E339200T1
Authority
AT
Austria
Prior art keywords
hyperuricemia
treatment
Prior art date
Application number
AT03292973T
Other languages
English (en)
Inventor
Robert Boizel
Pascale Fouqueray
Daniel Guerrier
Jean-Jacques Zeller
Bertrand Brutzkus
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of ATE339200T1 publication Critical patent/ATE339200T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT03292973T 2003-11-28 2003-11-28 Behandlung von hyperurikämie ATE339200T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03292973A EP1535612B1 (de) 2003-11-28 2003-11-28 Behandlung von Hyperurikämie

Publications (1)

Publication Number Publication Date
ATE339200T1 true ATE339200T1 (de) 2006-10-15

Family

ID=34443102

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03292973T ATE339200T1 (de) 2003-11-28 2003-11-28 Behandlung von hyperurikämie
AT04797525T ATE366570T1 (de) 2003-11-28 2004-11-02 Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04797525T ATE366570T1 (de) 2003-11-28 2004-11-02 Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie

Country Status (19)

Country Link
US (2) US20070099854A1 (de)
EP (2) EP1535612B1 (de)
JP (1) JP2007512267A (de)
KR (1) KR20060111541A (de)
CN (1) CN1886129A (de)
AR (1) AR046676A1 (de)
AT (2) ATE339200T1 (de)
AU (1) AU2004294686B2 (de)
BR (1) BRPI0417003A (de)
CA (1) CA2547543A1 (de)
CY (1) CY1105308T1 (de)
DE (2) DE60308390T2 (de)
DK (1) DK1535612T3 (de)
ES (2) ES2272926T3 (de)
PT (1) PT1535612E (de)
RU (1) RU2006122852A (de)
SI (1) SI1535612T1 (de)
WO (1) WO2005053676A1 (de)
ZA (1) ZA200605302B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7823417B2 (en) * 2005-11-04 2010-11-02 Ocv Intellectual Capital, Llc Method of manufacturing high performance glass fibers in a refractory lined melter and fiber formed thereby
CN103980267B (zh) * 2013-02-08 2018-02-06 镇江新元素医药科技有限公司 一类新型黄嘌呤氧化酶抑制剂的化合物及其药物组合物
WO2025021184A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码尿酸氧化酶的多核苷酸及其相关组合物和方法
CN121337784B (zh) * 2025-12-19 2026-04-17 济南微生态生物医学省实验室 3-羟基戊二酸在制备预防和/或治疗高尿酸相关疾病的药物中的应用及防治药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787789B1 (fr) * 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
AU2852100A (en) * 1999-01-19 2000-08-29 Tularik Inc. Methods of modulating uric acid levels
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
JP2004528329A (ja) * 2001-04-18 2004-09-16 メルク　エンド　カムパニー　インコーポレーテッド 炎症を処置するためのＰＰＡＲα〜γのリガンドまたはアゴニスト
SE0101981D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

Also Published As

Publication number Publication date
ES2286692T3 (es) 2007-12-01
PT1535612E (pt) 2006-12-29
EP1686983A1 (de) 2006-08-09
US20070099854A1 (en) 2007-05-03
ZA200605302B (en) 2007-04-25
AU2004294686A1 (en) 2005-06-16
WO2005053676A1 (en) 2005-06-16
ATE366570T1 (de) 2007-08-15
ES2272926T3 (es) 2007-05-01
DE60308390D1 (de) 2006-10-26
US20100160410A1 (en) 2010-06-24
CA2547543A1 (en) 2005-06-16
AU2004294686B2 (en) 2010-07-15
EP1686983B1 (de) 2007-07-11
DK1535612T3 (da) 2007-02-12
EP1535612A1 (de) 2005-06-01
CY1105308T1 (el) 2010-03-03
EP1535612B1 (de) 2006-09-13
CN1886129A (zh) 2006-12-27
DE602004007546D1 (de) 2007-08-23
JP2007512267A (ja) 2007-05-17
BRPI0417003A (pt) 2007-01-16
KR20060111541A (ko) 2006-10-27
AR046676A1 (es) 2005-12-14
SI1535612T1 (sl) 2006-12-31
RU2006122852A (ru) 2008-01-10
DE602004007546T2 (de) 2008-01-31
DE60308390T2 (de) 2007-09-06

Similar Documents

Publication Publication Date Title
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
EP1742675A4 (de) Behandlung von biomedizinischem abfall
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60322582D1 (de) Oberflächenbehandlung von medizinischem gerät
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
FI20060154L (fi) Neurogeneratiivisten tilojen hoito
DE60325353D1 (de) Behandlung von mukositis
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE369136T1 (de) Therapeutische behandlung
DE502004011696D1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DE602004026773D1 (de) Verfahrensherstellung von ethern
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE526970T1 (de) Behandlung von mastitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535612

Country of ref document: EP